MDMyriam Drysdale

Myriam Drysdale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Myriam Drysdale has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection

    by Myriam Drysdale, Rose Chang, Shuang Wang, Anna Coutinho, Vera Gielen, Theo Man, Rui Song, Mei Sheng Duh, Mandana Khalili, Dickens Theodore

    Hepatitis B surface antigen (HBsAg) loss is associated with improved clinical outcomes in patients with chronic hepatitis B virus (HBV) infection based on studies predominantly in Asian populations. We assessed real‐world associations between HBsAg loss and long‐term clinical outcomes in a diverse US population with chronic HBV infection. This retrospective cohort study (January 2012–December 2019) used Optum electronic health records data from patients with chronic HBV infection, identified via diagnosis codes or laboratory assessments. Patients with advanced liver disease and hepatitis C, hepatitis D or HIV co‐infection at baseline were excluded. Associations between HBsAg loss, as a proxy of functional cure, and clinical outcomes were assessed using doubly robust inverse probability of treatment‐weighted Cox proportional hazards models. In total, 15,760 patients with chronic HBV infection were included; 5.6% were receiving stable antiviral treatment. Overall, 4.2% ( n = 667) experienced HBsAg loss across the study period. HBsAg loss was associated with an 89% and 62% reduced risk of hepatocellular carcinoma (HCC; adjusted hazard ratio [aHR]: 0.11, 95% CI: 0.01–0.76) and all‐cause mortality (ACM; aHR: 0.38, 95% CI: 0.20–0.74), respectively. Risks of compensated cirrhosis (aHR: 0.84, 95% CI: 0.52–1.35) and decompensated liver disease (aHR: 0.74, 95% CI: 0.37–1.48) were lower after HBsAg loss, but did not reach significance. In this large, diverse population of patients with chronic HBV infection without advanced liver disease, HBsAg loss was associated with reduced risks of HCC and ACM compared with those without HBsAg loss.


  • Open Access

    Characterisation of People Living With Chronic Hepatitis B Virus Infection in England and Stratification by HBsAg Levels: A Cross‐Sectional Study

    by Myriam Drysdale, Iain A. Gillespie, Dina Christensen, Jim Davies, Kerrie Woods, Gail Roadknight, Stephanie Little, Hizni Salih, Kinga A. Várnai, Theresa Noble, et al.

    Characterisation of people with hepatitis B (PwHB) remains limited, particularly regarding treatment status, disease severity and biomarker profiles. Quantitative hepatitis B surface antigen (qHBsAg) is a key predictor of response to emerging therapies, but its distribution is poorly described. Using a large, ethnically diverse UK cohort, we assessed demographics, clinical features and HBsAg levels to guide treatment strategies. This cross‐sectional analysis of PwHB ( N = 2000 [prespecified]) used data from four English hospitals, collected via the National Institute for Health and Care Research Health Informatics Collaborative framework. Individual characteristics were assessed overall, and post hoc by qHBsAg levels (≤ 3000/> 3000 IU/mL; < 100/≥ 100–≤ 1000/> 1000 IU/mL) available from one centre ( N = 457). The cohort had a slight male predominance (54%) and a mean age of 44.9 years. White and Asian ethnicity each accounted for 25%, and 23% were on nucleos(t)ide analogue therapy. Centres collecting HBsAg data had more individuals with undetectable HBV DNA or on treatment. Among individuals with non‐missing qHBsAg data (263/457), 167/263 (63.5%) had qHBsAg ≤ 3000 IU/mL. These were older (49.6 vs. 43.5 years), more likely to be male (53.9% vs. 35.4%), Asian (40.7% vs. 20.8%) or have undetectable HBV DNA (35.9% vs. 17.7%), and less likely to be Black (13.2% vs. 34.4%) versus those with qHBsAg > 3000 IU/mL. Fifty‐six (21.3%) people had qHBsAg < 100 IU/mL, 60 (22.8%) between ≥ 100 and ≤ 1000 IU/mL, and 147 (55.9%) > 1000 IU/mL. This cohort of PwHB highlights qHBsAg distribution in clinical settings and could identify people more likely to achieve functional cure with emerging therapies.


  • Open Access

    Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in Asians With Chronic Hepatitis B Virus Infection

    by Wallis Lau, Myriam Drysdale, Eleonora Morais, Luis Antunes, Loey Mak, Christopher Lee, Catarina Camarinha, Xiaohui Sun, Adrienne Y.L. Chan, May Lam, et al.

  • Open Access

    Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data

    by Myriam Drysdale, Rose Chang, Tracy Guo, Mei Sheng Duh, Jennifer Han, Helen Birch, Catherine Sharpe, Daisy Liu, Sarah Kalia, Melissa Van Dyke, et al.

    Purpose: To assess the impact of early sotrovimab treatment versus no treatment on the risk of developing post-acute sequelae of COVID-19 (PASC; long COVID) in patients (age ≥ 12 years) with COVID-19 at high risk for progression to severe disease. Methods: Retrospective cohort study using the US National COVID Cohort Collaborative (N3C) data. Phase 1 identified and assessed multiple definitions of PASC; Phase 2 evaluated the effectiveness of sotrovimab for reducing the risk of PASC, utilizing definitions from Phase 1. Average treatment effect in the treated (ATT)-weighted Cox proportional hazards regression models were used to compare time to event for PASC between high-risk patients who received sotrovimab treatment between May 26, 2021 and April 5, 2022, and high-risk patients with COVID-19 diagnosed between May 26, 2021 and March 26, 2022 who did not receive any treatment for COVID-19 during the acute phase or any pre-exposure prophylaxis against SARS-CoV-2. Results: A total of 9,504 sotrovimab-treated and 619,668 untreated patients were included in the main analysis. Most baseline characteristics were balanced between the two cohorts after ATT weighting. The doubly robust ATT-weighted hazard ratio (95% confidence interval) was 0.92 (0.89–0.96) (p < 0.001), indicating that sotrovimab use was associated with a significantly lower risk of PASC. Results remained consistent in sensitivity analyses. Conclusion: In patients at high risk for severe COVID-19, the benefits of early sotrovimab treatment may extend beyond the acute phase of COVID-19 and contribute to the prevention of PASC symptoms.


  • Open Access

    Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study

    by Myriam Drysdale, Holly Tibble, Vishal Patel, Daniel C. Gibbons, Emily J. Lloyd, William Kerr, Calum Macdonald, Helen J. Birch, Aziz Sheikh

    Background: The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receiving early COVID-19 treatments in Scotland. Methods: Retrospective cohort study of non-hospitalized patients diagnosed with COVID-19 from December 1, 2021–October 25, 2022, using Scottish administrative health data. We included adult patients who met ≥ 1 of the National Health Service highest risk criteria for early COVID-19 treatment and received outpatient treatment with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or no early COVID-19 treatment. Index date was defined as the earliest of COVID-19 diagnosis or early COVID-19 treatment. Baseline characteristics and acute clinical outcomes in the 28 days following index were reported. Values of ≤ 5 were suppressed. Results: In total, 2548 patients were included (492: sotrovimab, 276: nirmatrelvir/ritonavir, 71: molnupiravir, and 1709: eligible highest risk untreated). Patients aged ≥ 75 years accounted for 6.9% (n = 34/492), 21.0% (n = 58/276), 16.9% (n = 12/71) and 13.2% (n = 225/1709) of the cohorts, respectively. Advanced renal disease was reported in 6.7% (n = 33/492) of sotrovimab-treated and 4.7% (n = 81/1709) of untreated patients, and ≤ 5 nirmatrelvir/ritonavir-treated and molnupiravir-treated patients. All-cause hospitalizations were experienced by 5.3% (n = 25/476) of sotrovimab-treated patients, 6.9% (n = 12/175) of nirmatrelvir/ritonavir-treated patients, ≤ 5 (suppressed number) molnupiravir-treated patients and 13.3% (n = 216/1622) of untreated patients. There were no deaths in the treated cohorts; mortality was 4.3% (n = 70/1622) among untreated patients. Conclusions: Sotrovimab was often used by patients who were aged < 75 years. Among patients receiving early COVID-19 treatment, proportions of 28-day all-cause hospitalization and death were low.


  • Open Access

    Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England

    by Vishal Patel, Bethany Levick, Stephen Boult, Daniel C. Gibbons, Myriam Drysdale, Emily J. Lloyd, Moushmi Singh, Helen J. Birch

    Background: The impact of the constantly evolving severe acute respiratory syndrome coronavirus 2 on the effectiveness of early coronavirus disease 2019 (COVID-19) treatments is unclear. Here, we report characteristics and acute clinical outcomes of patients with COVID-19 treated with a monoclonal antibody (mAb; presumed to be sotrovimab) across six distinct periods covering the emergence and predominance of Omicron subvariants (BA.1, BA.2, and BA.5) in England. Methods: Retrospective cohort study using data from the Hospital Episode Statistics database from January 1–July 31, 2022. Included patients received a mAb delivered by a National Health Service (NHS) hospital as a day-case, for which the primary diagnosis was COVID-19. Patients were presumed to have received sotrovimab based on NHS data showing that 99.98% of COVID-19-mAb-treated individuals received sotrovimab during the study period. COVID-19-attributable hospitalizations were reported overall and across six distinct periods of Omicron subvariant prevalence. Subgroup analyses were conducted in patients with severe renal disease and active cancer. Results: Among a total of 10,096 patients, 1.0% (n = 96) had a COVID-19-attributable hospitalization, 4.6% (n = 465) had a hospital visit due to any cause, and 0.3% (n = 27) died due to any cause during the acute period. COVID-19-attributable hospitalization rates were consistent among subgroups, and no significant differences were observed across periods of Omicron subvariant predominance. Conclusions: Levels of COVID-19-attributable hospitalizations and deaths were low in mAb-treated patients and among subgroups. Similar hospitalization rates were observed whilst Omicron BA.1, BA.2, and BA.5 were predominant, despite reported reductions in in vitro neutralization activity of sotrovimab against BA.2 and BA.5.


  • Open Access

    Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review

    by Myriam Drysdale, Mehmet Berktas, Daniel C. Gibbons, Catherine Rolland, Louis Lavoie, Emily J. Lloyd

    Purpose: To evaluate clinical outcomes associated with sotrovimab use during Omicron BA.2 and BA.5 predominance. Methods: Electronic databases were searched for observational studies published in peer-reviewed journals, preprint articles and conference abstracts from January 1, 2022 to February 27, 2023. Results: The 14 studies identified were heterogeneous in terms of study design, population, endpoints and definitions. They included > 1.7 million high-risk patients with COVID-19, of whom approximately 41,000 received sotrovimab (range n = 20–5979 during BA.2 and n = 76–1383 during BA.5 predominance). Four studies compared the effectiveness of sotrovimab with untreated or no monoclonal antibody treatment controls, two compared sotrovimab with other treatments, and three single-arm studies compared outcomes during BA.2 and/or BA.5 versus BA.1. Five studies descriptively reported rates of clinical outcomes in patients treated with sotrovimab. Rates of COVID-19-related hospitalization or mortality (0.95–4.0% during BA.2; 0.5–2.0% during BA.5) and all-cause mortality (1.7–2.0% during BA.2; 3.4% during combined BA.2 and BA.5 periods) among sotrovimab-treated patients were consistently low. During BA.2, a lower risk of all-cause hospitalization or mortality was reported across studies with sotrovimab versus untreated cohorts. Compared with other treatments, sotrovimab was associated with a lower (molnupiravir) or similar (nirmatrelvir/ritonavir) risk of COVID-19-related hospitalization or mortality during BA.2 and BA.5. There was no significant difference in outcomes between the BA.1, BA.2 and BA.5 periods. Conclusions: This systematic literature review suggests continued effectiveness of sotrovimab in preventing severe clinical outcomes during BA.2 and BA.5 predominance, both against active/untreated comparators and compared with BA.1 predominance.


  • Open Access

    Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study

    by Myriam Drysdale, Evgeniy R Galimov, Marcus James Yarwood, Vishal Patel, Bethany Levick, Daniel C Gibbons, Jonathan D Watkins, Sophie Young, Benjamin F Pierce, Emily J Lloyd, et al.

    Background We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in highest-risk COVID-19 patients during Omicron predominance. Methods Retrospective cohort study using the Discover dataset in North West London. Included patients were non-hospitalised, aged ≥12 years and met ≥1 National Health Service highest-risk criterion for sotrovimab treatment. We used Cox proportional hazards models to compare HRs of 28-day COVID-19-related hospitalisation/death between highest-risk sotrovimab-treated and untreated patients. Age, renal disease and Omicron subvariant subgroup analyses were performed. Results We included 599 sotrovimab-treated patients and 5191 untreated patients. Compared with untreated patients, the risk of COVID-19 hospitalisation/death (HR 0.50, 95% CI 0.24, 1.06; p=0.07) and the risk of COVID-19 hospitalisation (HR 0.43, 95% CI 0.18, 1.00; p=0.051) were both lower in the sotrovimab-treated group; however, statistical significance was not reached. In the ≥65 years and renal disease subgroups, sotrovimab was associated with a significantly reduced risk of COVID-19 hospitalisation, by 89% (HR 0.11, 95% CI 0.02, 0.82; p=0.03) and 82% (HR 0.18, 95% CI 0.05, 0.62; p=0.007), respectively. Conclusions Risk of COVID-19 hospitalisation in sotrovimab-treated patients aged ≥65 years and with renal disease was significantly lower compared with untreated patients. Overall, risk of hospitalisation was also lower for sotrovimab-treated patients, but statistical significance was not reached.


  • Open Access

    Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium

    by Myriam Drysdale, Thor Hautekiet, Moushmi Singh, Joris Hautekiet, Linda Ludikhuyze, Vishal Patel, Daniel C Gibbons, Dorothée De Roeck, Kirsten Colpaert, Emily J Lloyd, et al.

    Background: Sotrovimab, a dual-action, engineered human monoclonal antibody, has been demonstrated to significantly reduce the risk of hospitalization and death in high-risk patients with COVID-19. Here, we describe the real-world use of, and outcomes from, sotrovimab treatment in Belgium during the Delta and Omicron waves among patients with COVID-19 at high risk of developing severe disease.Methods: This was a multicentric, single-arm observational cohort study of non-hospitalized patients receiving outpatient sotrovimab treatment between 1 November 2021 and 2 August 2022. We performed a retrospective analysis of hospital, pharmacy and administrative data from nine hospitals in Belgium. The primary outcomes were all-cause and COVID-19-related hospitalizations and all-cause deaths during the 29-day acute follow-up period from first administration of sotrovimab.Results: A total of 634 patients were included in the analysis (63.4% aged n= 429/634) of patients were immunocompromised, with 36.9% (n= 234/634) actively treated for malignancy. During the 29-day acute period, 12.5% (n= 79/634) of sotrovimab-treated patients were hospitalized due to any cause (median duration 4 days; median time to hospitalization 14 days) and 1.1% (n= 7/634) died due to any cause. In total, 0.8% (n= 5/634) of patients were admitted to an intensive care unit (ICU). COVID-19-related hospitalization was experienced by 2.5% (n= 16/634) of patients (median duration 10 days; median time to hospitalization 10.5 days), with 0.5% (n= 3/634) of patients admitted to an ICU. COVID-19-related hospitalization was experienced by 6.3% (n= 3/48) of patients during Delta predominance (04/11/2021–23/12/2021), 6.3% (n= 1/16) of patients during Delta/BA.1 codominance (24/12/2021–01/01/2022), 1.4% (n= 3/218) of patients during BA.1 predominance (02/01/2022–09/02/2022), 2.1% (n= 2/97) of patients during BA.1/BA.2 codominance (10/02/2022–07/03/2022) and 2.7% (n= 7/255) of patients during BA.2/BA.5 codominance (08/03/2022–02/08/2022).Conclusions: This observational study demonstrated consistently low rates of COVID-19-related hospitalizations and all-cause deaths in sotrovimab-treated patients during the Omicron subvariant periods in Belgium, despite over two-thirds of the study population being immunocompromised. Comparative effectiveness studies are warranted to confirm sotrovimab effectiveness in highly immunocompromised patients with COVID-19.

  • Open Access

    Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review

    by Myriam Drysdale, Mehmet Berktas, Daniel C. Gibbons, Catherine Rolland, Louis Lavoie, Emily J. Lloyd

    Background Emerging SARS-CoV-2 variants have impacted the in vitro activity of sotrovimab, with variable fold changes in neutralization potency reported for Omicron BA.2 and subsequent variants. We performed a systematic literature review (SLR) to evaluate clinical outcomes associated with sotrovimab use during Omicron BA.2 and BA.5 predominance. Methods Electronic databases were searched for observational studies published in peer-reviewed journals, preprint articles and conference abstracts from January 1, 2022–February 27, 2023. Results The 14 studies identified were heterogeneous in terms of study design, population, endpoints and definitions, and comprised >1.7 million high-risk patients with COVID-19, of whom approximately 41,000 received sotrovimab (range n=20– 5979 during BA.2 and n=76–1383 during BA.5 predominance). Studies were from the US, UK, Italy, Denmark, France, Qatar, and Japan. Four studies compared the effectiveness of sotrovimab with untreated or no monoclonal antibody treatment controls, two compared sotrovimab with other treatments, and three single-arm studies compared outcomes during BA.2 and/or BA.5 versus BA.1. The remaining five studies descriptively reported rates of clinical outcomes in patients treated with sotrovimab. Rates of COVID-19-related hospitalization or mortality among sotrovimab-treated patients were consistently low (0.95% to 4.0% during BA.2; 0.5% to 2.0% during BA.5). All-cause hospitalization or mortality was also low (1.7% to 2.0% during BA.2; 3.4% during combined BA.2 and BA.5 periods). During BA.2, a lower risk of all-cause hospitalization or mortality was reported across studies with sotrovimab versus untreated cohorts. Compared with other treatments, sotrovimab was associated with a lower (molnupiravir) or similar (nirmatrelvir/ritonavir) risk of COVID-19-related hospitalization or mortality during BA.2 and BA.5. There was no significant difference in outcomes between the BA.1, BA.2 and BA.5 periods. Conclusions The studies included in this SLR suggest continued effectiveness of sotrovimab in preventing severe clinical outcomes during BA.2 and BA.5 predominance, both against an active/untreated comparator and compared with BA.1 predominance.